Citadel Advisors’s Tarsus Pharmaceuticals TARS Stock Holding History

Citadel Advisors’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$224K	Buy	+3,200	New	+$224K	﹤0.01%	11174
2025 Q2	–	Sell	-7,600	Closed	-$390K	–	15023
2025 Q1	$390K	Sell	7,600 -21,800	-74%	-$1.08M	﹤0.01%	9016
2024 Q4	$1.63M	Buy	29,400 +25,300	+617%	+$1.15M	﹤0.01%	6062
2024 Q3	$135K	Buy	4,100 +2,400	+141%	+$67.5K	﹤0.01%	10697
2024 Q2	$46.2K	Sell	1,700 -20,600	-92%	-$693K	﹤0.01%	11850
2024 Q1	$811K	Buy	22,300 +15,100	+210%	+$444K	﹤0.01%	7376
2023 Q4	$146K	Buy	7,200 +7,000	+3,500%	+$117K	﹤0.01%	10434
2023 Q3	$3.55K	Sell	200 -3,500	-95%	-$61.9K	﹤0.01%	13572
2023 Q2	$66.9K	Buy	3,700 +1,300	+54%	+$20.7K	﹤0.01%	11457
2023 Q1	$30.2K	Buy	2,400 +2,200	+1,100%	+$32.2K	﹤0.01%	12736
2022 Q4	$2.93K	Buy	+200	New	+$3.31K	﹤0.01%	14268

Other funds holding TARS

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citadel Advisors's TARS Position: Q1 2026 in Review

Citadel Advisors opened a new position in Tarsus Pharmaceuticals (TARS) in Q1 2026: 163,997 shares worth $11.5M. The stake represents ﹤0.01% of the portfolio and ranks #3062 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in TARS as recently as Q3 2025.

Citadel Advisors first reported a position in TARS in Q1 2022 and has held it in 15 quarters since. The position peaked at $51M in Q1 2025. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

Citadel Advisors held 163,997 shares of Tarsus Pharmaceuticals worth $11.5M as of Q1 2026.
Tarsus Pharmaceuticals was a new Citadel Advisors position in Q1 2026.
Tarsus Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3062 holding.
Citadel Advisors first reported a position in Tarsus Pharmaceuticals in Q1 2022 and has held it in 15 quarters since.
Citadel Advisors's Tarsus Pharmaceuticals position peaked at $51M in Q1 2025.
253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.